Aimovig (erenumab-aooe) / Amgen, Novartis - LARVOL DELTA

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis. (PubMed, J Headache Pain) - No abstract available

Journal • Review • CNS Disorders • Migraine • Pain

Drugs for Migraine Prophylaxis. (PubMed, Dtsch Arztebl Int) - "The new prophylactic drugs against migraine are effective, well-tolerated, and especially useful for patients for whom traditional oral migraine prophylactic drugs and onabotulinum toxin A are ineffective, not tolerated, or contraindicated."

Journal • CNS Disorders • Migraine • Pain

Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER Study. (PubMed, Neurol Clin Pract) - P3 | "These results enhance the evidence for erenumab as an effective preventive therapy for patients with EM. Clinicaltrials.gov/study/NCT03333109."

Journal • CNS Disorders • Migraine • Pain

Aimovig: Regulatory submission for pediatric migraine in 2028 (Novartis) - Q4 2025 Results

Filing • CNS Disorders • Migraine • Pain

Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab. (PubMed, Cureus) - "She experienced persistent migraines despite valproic acid and sumatriptan use. After the administration of intravenous methylprednisolone (IVMP), ofatumumab treatment was introduced; erenumab was later initiated to manage migraines...The combination therapy demonstrated effectiveness without exacerbating the patient's underlying dermatological condition. This case suggests that combining ofatumumab and erenumab is a viable therapeutic option for patients with MS and comorbid migraine and pyoderma gangrenosum, offering effective disease control with an acceptable safety profile."

Journal • CNS Disorders • Migraine • Multiple Sclerosis • Pain • Pyoderma Gangrenosum

OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) - P3 | N=284 | Completed | Sponsor: Amgen | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Migraine • Pain • Pediatrics

Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis. (PubMed, Eur J Clin Pharmacol) - "fremanezumab offers the best balance of efficacy and safety. Further long-term studies are needed."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain

A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine. (PubMed, J Neurol Sci) - "This study highlighted the role of early response in predicting the long-term response to CGRP mAbs. We also emphasized the importance of documenting satisfaction, migraine aura frequency, in addition to migraine frequency, for deeper insights into migraine pathophysiology."

Journal • Observational data • CNS Disorders • Migraine • Pain

CHAIRS: China HeadAche DIsorders RegiStry (clinicaltrials.gov) - P=N/A | N=10000 | Recruiting | Sponsor: Beijing Tiantan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

Comparative effects of anti-CGRP monoclonal antibodies and atogepant on migraine disability, sleep quality, and attack frequency: A 12-month observational study (EHF-EHC 2025) - " This retrospective observational study included patients with chronic migraine refractory to first-line preventives, treated with erenumab, galcanezumab, fremanezumab, or atogepant. Anti-CGRP therapies reduced migraine burden in patients with refractory chronic migraine. Notably, erenumab was associated with a strong correlation between disability and sleep quality. Atogepant showed promising early improvements in sleep in selected patients."

Clinical • Observational data • CNS Disorders • Migraine • Pain • Sleep Disorder

Combining anti-CGRP antibodies with atogepant: Safety and efficacy in a patient cohort (EHF-EHC 2025) - "Treatments included erenumab (n=1), fremanezumab (n=11), galcanezumab (n=6), and eptinezumab (n=9). In this real-world cohort, combining antiCGRP mAbs with atogepant appears to be safe and may offer additional benefit."

Clinical • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Insomnia • Migraine • Sleep Disorder

Four-year real-world efficacy and tolerability of anti-CGRP therapies in a tertiary headache centre in England (EHF-EHC 2025) - " A total of 548 treatments were initiated in 415 patients (rimegepant: n=57; atogepant: n=60; erenumab: n=283; fremanezumab: n=136; galcanezumab: n=12). Real-world efficacy broadly aligns with clinical trial data, though our galcanezumab findings are limited by small sample size. While direct comparisons outside of randomised trials are limited, agents differed in both effectiveness and tolerability. Rimegepant was well tolerated but was associated with the lowest effectiveness at 12 weeks."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Satisfaction rates and self-reported adverse events of antiCGRP therapies for migraine prevention – Focus on patient perspectives (EHF-EHC 2025) - "4% of questionnaires corresponded to patients on Atogepant, 9.3% on Erenumab , 24.4% on Eptinezumab, 29% on Galcanezumab and 32% on Fremanezumab. More than half of our patients reported significant improvement with antiCGRP therapy. Selfreported adverse events were more frequent (56%) than previously reported. Most frequent, were gastrointestinal symptoms and local skin reactions."

Adverse events • Clinical • Cardiovascular • CNS Disorders • Hypertension • Migraine • Pain

Middle meningeal artery lidocaine infusion for refractory migraine: First case report in Portugal (EHF-EHC 2025) - "Various pharmacologic classes were tried without benefit: antihypertensives and calcium channel blockers (propranolol, candesartan, flunarizine), antiepileptics (valproic acid, topiramate, oxcarbazepine), antidepressants (amitriptyline, nortriptyline, venlafaxine, fluvoxamine, sertraline, clomipramine), other preventives (prednisolone, oxitriptan, melatonin), cycles of botulinum toxin (PREEMPT protocol), monoclonal antibodies (galcanezumab, fremanezumab, erenumab), and atogepant. At the time of the procedure, the patient was on eptinezumab 100 mg and botulinum toxin every three months but continued to have daily headaches, with severe intensity and reliance on eletriptan for acute relief... MMA lidocaine infusion has been described in few cases, and this is, to our knowledge, the first reported in Portugal. It constitutes an invasive therapeutic approach that should be considered only as a rescue option for carefully selected patients with severely refractory migraine...."

Case report • Clinical • Anorexia • CNS Disorders • Migraine • Pain

Local cutaneous complications of CGRP monoclonal antibodies: A case series (EHF-EHC 2025) - " Nine women treated with subcutaneous antiCGRP monoclonal antibodies developed mild/moderate local cutaneous reactions (mainly erythema, induration, edema, and pruritus) representing 5% of all treated patients (n=190; fremanezumab 88, galcanezumab 75, erenumab 27)...Two continued therapy with supportive measures (local cooling, topical corticosteroid cream, pre/post-injection antihistamines, and rotation of injection site to abdominal area), while five required switching due to persistent reactions with or without lack of efficacy: two to atogepant, one to erenumab then eptinezumab, and one directly to eptinezumab; one discontinued... Local cutaneous reactions to subcutaneous anti-CGRP monoclonal antibodies occurred in nearly 5% of patients and were generally mild. Supportive measures allowed continuation in some cases, but most required switching to another monoclonal antibody or a gepant. Monitoring and proactive management are essential to minimize treatment..."

Clinical • CNS Disorders • Dermatology • Immunology • Migraine • Pruritus

MIGRA-MS: A case series on chronic migraine and multiple sclerosis (EHF-EHC 2025) - "Prior treatments included interferons and glatiramer acetate; current therapies consisted of ocrelizumab, natalizumab, alemtuzumab, teriflunomide, or dimethyl fumarate...All received a median of three classic preventives (amitriptyline in all cases) and onabotulinumtoxinA (PREEMPT, 155 IU) with only one responder; two patients received an extended dose (195 IU) without benefit and later CGRP monoclonal antibodies (galcanezumab, erenumab, eptinezumab) with no response, and atogepant with only transient or partial benefit... Migraine is more prevalent in MS patients than in the general population, and their coexistence represents a therapeutic challenge. In this case series of relapsing–remitting MS with chronic resistant migraine, response to onabotulinumtoxinA and antiCGRP therapies was limited, with no drug interactions or adverse effects observed. An individualized approach and further studies are needed to assess emerging treatments in this subgroup."

Clinical • CNS Disorders • Migraine • Multiple Sclerosis • Pain

Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. (PubMed, J Headache Pain) - No abstract available

Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain

CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies prophylaxis (EHF-EHC 2025) - " From Feb 2022 to Feb 2023, we enrolled 56 migraineurs who began prophylaxis with erenumab (n=26), galcanezumab (n=16), or fremanezumab (n=14). Anti-CGRP(R) mAbs are very effective migraine prophylactic agents. Galcanezumab significantly reduced plasma CGRP by 3 months, with near-undetectable levels at 6 months, consistent with its CGRP-binding mechanism and prior studies. In contrast, erenumab did not affect significantly CGRP plasmatic levels, potentially due to its different binding site on the CGRP receptor."

Clinical • CNS Disorders • Migraine • Pain • ADCYAP1

Comparison of functional responses to CGRP and related peptides in human middle meningeal and superficial temporal arteries (EHF-EHC 2025) - "Our aim was to compare the vasodilatory responses of extracranial human superficial temporal arteries (HSTA) and intracranial middle meningeal arteries (HMMA) to CGRP, the amylin analogue pramlintide, and adrenomedullin 2 (AM2), as well as the inhibition induced by the CGRP receptor-binding monoclonal antibody erenumab and the CGRP receptor antagonist olcegepant. The comparable responses of HSTA (innervated by V3) and HMMA (innervated by V1) to CGRP, pramlintide and AM2 do not challenge the potential role of extracranial arteries in the pathophysiology of migraine. Similar CGRP inhibition in both arteries may contribute to the antimigraine effects of CGRP receptor-targeting medications at either location. Finally, these results may also suggest that pain pathways relevant to migraine may overlap with those implicated in temporomandibular disorders."

CNS Disorders • Giant Cell Arteritis • Migraine • Musculoskeletal Diseases • ADM

Reporting of lack of efficacy of anti-CGRP monoclonal antibodies in migraine patients treated with other concomitant monoclonal antibodies: A VigiBase disproportionality analysis (EHF-EHC 2025) - " Reports listing erenumab, galcanezumab, fremanezumab, or eptinezumab as suspected or interacting drugs and collected in VigiBase up to March 9th, 2025 were included and classified as cases (reporting lack of efficacy) or non-cases (reporting other adverse drug reactions). The concomitant use of other mAbs in patients receiving anti-CGRP mAbs for migraine is not associated with increased reporting of lack of efficacy in VigiBase. These findings offer preliminary reassurance regarding the real-world effectiveness of anti-CGRP mAbs when administered in combinations with mAbs for other indications."

Clinical • CNS Disorders • Migraine • Pain

Is there an association between the effectiveness of anti-CGRP monoclonal antibodies in migraine and injection site reactions? (EHF-EHC 2025) - "The cohort included patients receiving erenumab (24.8%), galcanezumab (27.8%) and fremanezumab (47.4%). Local reactions at the injection site are a common occurrence, affecting nearly one-third of patients on subcutaneous anti-CGRP mAb therapy for migraine. However, our findings suggest that the presence of these reactions does not compromise the clinical efficacy of the treatment. While ISRs may cause patient discomfort, they do not appear to influence therapeutic outcomes."

CNS Disorders • Dermatology • Migraine • Pain

Clinical characteristics and treatment outcomes in resistant and refractory migraine: Application of the European Headache Federation (EHF) 2020 criteria in a UK tertiary headache cohort (EHF-EHC 2025) - "Galcanezumab looked to be significantly less effective compared with Erenumab (p=0.02). EHF 2020 Criteria for resistant and refractory migraine was applicable in our cohort. RM accounted more than one-quarter of our patients with a high proportion of migraine aura, depression, high BMI. Older rM patients seem to respond better to Erenumab compared to ligand antiCGRP."

Clinical • CNS Disorders • Depression • Migraine • Mood Disorders • Pain

Does Fibromyalgia improve with CGRP targeting therapy? (EHF-EHC 2025) - "The most commonly used CGRP monoclonal antibody was fremanezumab (63%), followed by erenumab (30%) and galcanezumab (7%). Our study showed that a minority of patients with migraine and fibromyalgia will experience improvement in their fibromyalgia symptoms with CGRP mAbs. This may suggest the underlying biology of fibromyalgia in patients with migraine is largely driven by mechanisms other than CGRP."

CNS Disorders • Fibromyalgia • Migraine • Musculoskeletal Pain • Otorhinolaryngology • Pain • Rheumatology • Vertigo

Eptinezumab for migraine prevention: Initial experience from a Portuguese tertiary hospital (EHF-EHC 2025) - "Prior anti-CGRP monoclonal antibody use was documented in 14 patients (78%), all of whom had previously received galcanezumab. Among them, 4 were also treated with fremanezumab, and 1 of these had additionally received erenumab... Eptinezumab offers distinct advantages. Nonetheless, in this cohort, it was not frequently selected as a first-line option, being primarily used in patients with highly refractory migraine. Treatment adherence was high and further data are needed to assess long-term effectiveness and better define its role in clinical practice."

Clinical • CNS Disorders • Migraine • Pain

Long-term efficacy and predictors of response of cgrp monoclonal antibodies in migraine prevention: A real-world service evaluation (EHF-EHC 2025) - "Most first received fremanezumab (n=157, 70%) or erenumab (n=65, 29%); one received galcanezumab. CGRP-mAbs are effective for most patients. Response is more likely in triptan responders and those starting later. Poorer outcomes with longer migraine duration, more premonitory symptoms, and prior failure of preventives support early initiation of mAbs for a better outcome."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain